COVID-19 Antibody Therapeutics Tracker

Legacy Manually Cleaned

The last update will be made in Aug. 1, 2021, after which, we will no longer maintain this dataset.

About this dataset

As the COVID-19 pandemic is the global healthcare crisis, scientists worldwide are collaborating to prevent or treat COVID-19. Antibody therapeutics hold enormous promise for treatment of COVID-19. Chinese Antibody Society is collaborating with our partner The Antibody Society to track the antibody-based therapeutics targeting COVID-19, to contribute our expertise to the globally joint efforts against the pandemic. In connection with the collaboration, The Antibody Society has published a “Coronavirus in the Crosshairs” series of articles addressing different aspects of therapeutics against COVID-19, and is continuous publishing new information and analysis. This tracker will be updated daily with the latest in developments for antibody therapeutics. If you notice an issue with this data or wish to submit an update, please contact us by email: Management@chineseantibody.org

References

This dataset has been described in the following mansucript. You are requested to cite the this article when you use the COVID-19 Antibody Therapeutics Tracker” from our paper:

  • Lifei Yang, Weihan Liu, Xin Yu, Meng Wu, Janice M Reichert, Mitchell Ho, COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19, Antibody Therapeutics
  • Stats at a Glance

    217

    Total Entries

    62

    Targets under investigation

    133 programs targeting S protein

    2

    Antibodies approved for treatment

    217 antibodies in phase 1 to 3

    203

    or more research groups and/or institutions

    52 or more countries

    Data Table

    Data Landscape

    Refinement Search

    This section is provided to help you refine search and quickly navigate to the references to the antibodies.

    Target

    Status

    Format

    Country